What Dr. Sumi Found, and What They Buried for 40 Years

What Dr. Sumi Found, and What They Buried for 40 Years

Chicago, 1980. One Petri Dish. Eighteen Hours.

There's a reason most cardiologists in America have never heard the name Hiroyuki Sumi.

In 1980, in a borrowed lab at the University of Chicago, a young Japanese researcher was doing something nobody had bothered to do before. He was screening dietary substances for fibrinolytic activity.

Fibrin is the protein scaffolding that holds your blood clots together. Fibrinolytic activity is the ability to break it apart. Pharmaceutical companies had spent two decades looking for a drug that could do it. The candidates they did find required hospital IV lines and trained staff to administer them.

Sumi was looking somewhere none of them had thought to look. The pantry.

He tested 173 foods. Most of them did nothing.

Then he placed a small sample of nattō, a fermented soybean preparation that had been a staple in the Kantō region of Japan for at least a thousand years, onto a plate of human fibrin. He went home for the night.

He came back 18 hours later...

The fibrin was gone. Not reduced. Not partially cleared. Gone.

A food, sitting on a hospital lab bench overnight, had done what no drug on the planet could do without a needle and a clinician.

He was the first person on the planet to watch it happen.

The Food Older Than the Country

I want to slow down on this part, because most people miss it.

Nattō is not a curiosity. It is not a wellness trend. It is breakfast.

It has been breakfast in the Kantō region of Japan for roughly a thousand years. 

That means it predates the printing press by centuries, and the founding of the United States by nearly nine of them. Sumi did not invent nattokinase. He gave it a name. The enzyme had been working inside Japanese bodies for a thousand years before anyone in a lab thought to look at what it was doing.

The recipe is two ingredients: 

• Soy beans, and
• Bacillus subtilis (natto):
  • A bacterium that ferments the soybeans into a sticky, stringy, sharply flavored food that most Americans have never tasted in their lives.

For most of that thousand years, Japanese epidemiologists have noticed something else.

The Kantō region has unusually low rates of stroke and heart attack. The standard explanations are the standard explanations: fish, lower body weight, a less sedentary culture. All of that is true. None of it is a complete answer.

Zoom out to the country level and the pattern only gets sharper.

Japan's age-standardized cardiovascular mortality runs at roughly half the U.S. rate.

Half. That is not a rounding error. That is two of the wealthiest countries on earth, with comparable medical infrastructure, looking at the same disease and arriving at a different floor of how many people it has to kill.

One of those countries figured out that part of the answer was sitting on the breakfast table.

What He Named It, and What It Actually Does

He called the enzyme nattokinase. *Natto* for the food. *Kinase* for the class of enzymes that cleaves a substrate. He published the work in 1987 in the journal *Experientia*. It was the first published demonstration of a dietary enzyme that worked through the same biochemical pathway as the body's own clot-clearing system.

Your body has that system already. It is called the fibrinolytic pathway. Plasmin, a serine protease, does most of the actual work. When fibrin builds up where it shouldn't, plasmin clears it. The pathway is meant to run in the background, for your entire life.

It does not, anymore. We will get to why.

What Sumi found is that nattokinase activates the same pathway from the outside. You eat it. It supports a job the body was already trying to do.

Now look at what the American cardiology toolkit is actually built to do:

• Statins reduce the production of cholesterol in the liver.
  • They do not clear arterial plaque already present at a level that matters; landmark trials measured single-digit regression after two years of high-dose therapy.
• Anticoagulants slow the formation of *new* clots.
  • They do not dissolve the clots you already have.
• Antiplatelet drugs reduce the clumping of platelets
  • so that *new* clots form less easily.
• Stents prop open a narrowed artery mechanically.
  • They do not remove what narrowed it.
• Bypass surgery routes blood around the blockage.
  • The blockage stays exactly where it was.

There is a pattern there, and it is not subtle. Every tool in the standard of care prevents what has not happened yet, or reroutes around what already has. Not one of them touches the fibrin that is already inside your arteries.

Sumi found the only dietary compound on record that does.

What Japan Did With It

This is the part of the story where two countries make two different choices about the same finding.

Japan studied it.

Through the 1990s and 2000s, Japanese cardiovascular literature absorbed the work. Researchers replicated the fibrinolytic effect across dozens of laboratories. They ran human trials on blood viscosity, on blood pressure, on plaque. By the 2010s, nattokinase was routine context in Japanese cardiology, sitting alongside diet, exercise, and statins in how cardiovascular care got discussed.

Then, in 2022, a research team published the largest clinical trial on the compound to date in Frontiers in Cardiovascular Medicine. 

• 1,062 patients.
• Twelve months.

The active arm showed a 36.6% reduction in carotid plaque size and a 21.7% reduction in the thickness of the artery wall itself, compared to baseline.

You need to sit with that number for a second.

The most celebrated statin plaque-regression trial of the last twenty years showed single-digit reductions in plaque volume after two full years of maximum-dose therapy.

The 2022 nattokinase trial showed a reduction roughly 4X times that magnitude, on a fermented food, in one year, in a peer-reviewed cardiology journal. Not a fringe journal. Cardiology's own literature.

Japan did not ban it. Did not bury it. Did not pretend it wasn't there. They folded it into the standard of care and moved on.

In the same window, Japanese cardiovascular mortality remained among the lowest in the developed world. American cardiovascular mortality remained the leading cause of death in the United States, the same position it has held for a century.

One country took the finding seriously. The other one did not.

The $400 Billion Reason You've Never Heard the Name

I want to name the enemy here. Specifically.

In 2024, the American Heart Association's own presidential advisory put U.S. cardiovascular healthcare costs at more than $400 billion a year, projected to triple to $1.34 trillion by 2050. That is what the disease costs the country. It is also, give or take, what the disease "earns" the country's largest medical-industrial sector every year.

Here is what that means at the level of one person.

A single American patient diagnosed with cardiovascular disease, on a statin plus an anticoagulant plus an antiplatelet drug, is worth roughly $2,000 to $4,000 a year to that industry. 

Every year. For the rest of their life. Run that out across a 25-year diagnosis-to-death window and you are looking at $50,000 to $100,000 per patient in drug revenue alone, before a single stent or bypass is added on top.

Multiply by 127.9 million American adults with cardiovascular disease, per the AHA's 2024 statistics report. Nearly half the adult population of the country.

Nattokinase costs about $30 a month. It is not refillable through your cardiologist's office.

Heart disease has been the leading cause of death in the United States for a hundred years. That is not a failure of the system. That is the system, operating exactly as designed. It is the most profitable patient population in American medicine, and the industry does not need a conspiracy to keep it that way. It just needs to keep paying for the research, the guidelines, and the education that decide what your cardiologist is allowed to know.

A 1,000-year-old food cannot be patented. That is the original sin of nattokinase in American medicine. Everything that follows is downstream of that one fact.

Here is how a 1980 finding ends up on a supplement company's blog in 2026 instead of in your doctor's chart notes. Six steps.

1. A finding emerges.
   1. The compound is a 1,000-year-old food. It cannot be owned.
2. No ownership means no Phase III.
   1. No pharmaceutical company will fund a $300 million pivotal trial for a compound their competitors can sell out of a bulk barrel the next morning. No Phase III means no FDA-recognized indication.
3.  No indication means no guideline.
   1. The ACC and AHA cardiovascular prevention guidelines do not list nattokinase. Search them today for *fibrinolytic* as a dietary target. It is not there.
4.  No guideline means no reimbursement.
   1. There is no CPT code for "screen for fibrin load." No billing code, no clinic workflow, no protocol.
5. No reimbursement means no continuing medical education.
   1. The conferences your cardiologist attends are funded by the companies whose drugs can be billed. The speakers are on consulting contracts with those same companies.
6. End of the line.
   1. A 1980 finding that should have been front-page cardiology news in 1987 is, in 2026, sitting on a supplement company's blog instead of in your chart.

 You are not crazy for not having heard this. The system that decides what your cardiologist knows is funded by people who profit when you take a drug and lose when you eat a food. The reason you've never heard the name Sumi is not that anyone buried him. It is that the industry never had a financial reason to dig him up.

Why Your Body Can No Longer Clear It On Its Own

Your body was built to do this work itself. Plasmin clears fibrin. The pathway is ancient. For most of human history, it was enough. Three things have changed:

First, the rate at which fibrin forms has gone up.

Chronic inflammation, the kind we now live in continuously, drives the body to lay down more fibrin than it used to. Seed oils. Ultra-processed food. Chronic sleep debt. Ambient cortisol from a culture that has not let anyone exhale since 2019. The body is on a hair trigger to wall things off, and fibrin is what it builds the walls with.

Second, plasmin activity declines with age.By forty, most Americans are running a cleanup crew that is slower than the demolition team. By fifty, the gap is wide enough to start showing up on a carotid ultrasound.

Third, modern environmental load is something the system never evolved to handle.

PM2.5 from chronic air pollution. Glycation end-products from a diet built on processed carbohydrate. And post-2020, an emerging body of literature on persistent spike-protein circulation that is not flattering to the fibrinolytic pathway. None of it is what your grandmother's body was tuned to clear.

Result: at exactly the age you most need it, your body's fibrin cleanup is overwhelmed. The plaque on the carotid ultrasound is not a moral failure. It is the predictable output of a thousand-year-old cleanup system running into a hundred-year-old environment it was never asked to handle.

Your grandmother's body cleared this on its own. Yours wasn't built for the world you live in.

Why No One Is Selling the Clean Version

Here is the last piece, and the one I have spent the most time on personally.

Most nattokinase on the American market is a mess. Three problems, in plain English.

1.Dose:

The clinical trials that produced the results worth talking about delivered roughly.

10,000 fibrinolytic units a day. Most consumer products on Amazon deliver two thousand. A fifth of a clinical dose, sold beside a label that name-drops the same studies it cannot replicate.

2. Strain:

Real nattokinase comes from a specific organism, Bacillus subtilis var. natto. A meaningful share of supplements are produced from generic Bacillus strains that look similar on a certificate of analysis and behave nothing like the original enzyme in the body. The label says "nattokinase." What is in the capsule frequently is not.

3. Stability:

Nattokinase is a protein. Proteins degrade. Heat kills it. Time degrades it. Stomach acid finishes the job if nothing protects it on the way through. Almost no product on the shelf publishes stability data, which means the enzyme that went into the capsule at the factory may not be the enzyme you swallow six months later in your kitchen.

A clean version means a clinical dose, the verified strain, real stability data, and a label that respects what you are actually trying to do. That version has not been built. That is what we have been working on.

There's more to come.

His Grandmother Ate This. Yours Didn't Know It Existed.

The science is not new. The food is not new. The enzyme is not new.

The only new part is that you are reading its name in English, in 2026, from a supplement company instead of from your cardiologist.

That is the only part of this story that is actually our fault to fix. We intend to.

Stay close. The next email goes out this week.

If you haven't read the first piece in this series, start there: Something Is Happening to American Hearts (And No One's Talking About It)

Reply if this landed. I read every one.

Antonio

Founder, Black Forest Supplements